We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo WHX Labs Dubai 2026 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`

By LabMedica International staff writers
Posted on 26 Oct 2022
Image: The new saliva-based PCR test kit can also be carried in the company`s COVID-19 vending machines (Photo courtesy of Shield T3)
Image: The new saliva-based PCR test kit can also be carried in the company`s COVID-19 vending machines (Photo courtesy of Shield T3)

With few travel restrictions in place and socializing back to normal, the annual winter rise in COVID-19 cases is "poised to collide with a resurgent influenza season, causing a 'twindemic' - or even a 'tripledemic,' with a third pathogen, respiratory syncytial virus, or R.S.V., in the mix. The three viruses have similar symptoms - fever, cough and congestion - but very different treatment methods, making quick identification important. Now, a new saliva-based PCR test kit can screen for the three illnesses - COVID-19, Influenza A/B and respiratory syncytial virus, or RSV – to meet the challenges of a potential "tripledemic" this winter.

The new test launched by Shield T3 (Champaign-Urbana, IL, USA), a spinout of the University of Illinois System's Discovery Partners Institute (Chicago, IL, USA), will help customers know within 24 hours if they have one of these three viruses. The Shield T3 kit, which is no bigger than a wallet, requires users to provide a small sample of drool and then mail the kit back to one of the company's CLIA-certified labs. Lab technicians run two separate tests on the sample, one for COVID, and one for flu and R.S.V.

The test kit is currently available to Shield T3 partners, including schools and companies, and also can be carried in the company's new COVID-19 vending machines, which are stocked with tests. The cost of the test is USD 70 or less, which represents significant savings over running the tests in a clinical setting. School administrators are able to access demand and positivity-rate data from the tests via an online dashboard.

"This is so much easier and less expensive than going to a campus clinic or a doctor," said David Clark, Shield T3's CEO. "We're working to become your partner for easy, rapid and accurate diagnostic tests from home, which is where you want to be if you're sick."

"Given the current state of the pandemic, when you're sick these days, you have no idea what you have; it could just be a cold, but it could be something, like COVID, that requires you to isolate," said Bill Jackson, Shield T3's principal officer. "This test gives our customers a quicker answer."

Related Links:
Shield T3
Discovery Partners Institute

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Pipette
Accumax Smart Series

Channels

Molecular Diagnostics

view channel
Image: The Monarch Mag Cell-free DNA (cfDNA) Extraction Kit provides isolation of low-abundance cfDNA from a range of biofluids (Photo courtesy of New England Biolabs)

New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more